Mechanism of action of rituximab, Anticancer Drugs, 2001. ,
,
, Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells, Cancer Res, vol.63, issue.2, pp.534-574, 2003.
Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, vol.26, pp.3629-3665, 2007. ,
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas, Blood, vol.101, issue.3, pp.949-54, 2003. ,
Anti-CD20 monoclonal antibodies: historical and future perspectives, Haematologica, vol.95, issue.1, pp.135-178, 2010. ,
Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther, vol.8, pp.87-100, 2013. ,
Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases, Autoimmun Rev, vol.12, issue.8, pp.854-863, 2013. ,
,
, Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis, N Engl J Med, vol.363, issue.3, pp.211-231, 2010.
,
, Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis, N Engl J Med, vol.371, pp.1771-80, 2014.
Rituximab for idiopathic membranous nephropathy, Lancet Lond Engl, vol.360, issue.9337, pp.923-927, 2002. ,
Rituximab treatment of idiopathic membranous nephropathy, Kidney Int, 2008. ,
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study, Clin J Am Soc Nephrol CJASN, vol.5, issue.12, pp.2188-98, 2010. ,
,
, Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy, J Am Soc Nephrol JASN, vol.22, issue.8, pp.1543-50, 2011.
,
, Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up, J Am Soc Nephrol JASN, vol.28, issue.1, pp.348-58, 2017.
Epidemiology and management of refractory lupus nephritis, Autoimmun Rev, vol.10, issue.11, pp.655-63, 2011. ,
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis, Arthritis Rheum, vol.64, issue.3, pp.843-53, 2012. ,
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome: Multicentric Report, Clin J Am Soc Nephrol, vol.5, issue.12, pp.2207-2219, 2010. ,
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy, J Am Soc Nephrol JASN, vol.4, issue.8, pp.2729-2766, 2009. ,
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response, J Cancer Sci Ther, vol.7, issue.11, 2015. ,
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies, BioDrugs Clin Immunother Biopharm Gene Ther, vol.25, issue.1, pp.13-25, 2011. ,
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, vol.348, issue.7, pp.601-609, 2003. ,
Immunogenicity of rituximab in patients with severe pemphigus, Clin Immunol Orlando Fla, vol.132, issue.3, pp.334-375, 2009. ,
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment, Arthritis Rheum, vol.54, issue.9, pp.2970-82, 2006. ,
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus, Ann Rheum Dis, vol.67, issue.12, pp.1724-1755, 2008. ,
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab, N Engl J Med, vol.376, issue.16, pp.1517-1543, 2017. ,
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs, vol.5, pp.826-863, 2013. ,
,
, Detection and quantification of rituximab in the human urine, J Immunol Methods, 2017.
Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome, Pediatr Nephrol, vol.30, issue.8, pp.1367-70, 2015. ,
Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome, Case Rep Nephrol, p.1372859, 2017. ,
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab, Ann Oncol Off J Eur Soc Med Oncol, vol.14, issue.4, pp.520-555, 2003. ,
Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis, Ann Rheum Dis, vol.69, issue.2, pp.409-421, 2010. ,
Interindividual variability of response to rituximab: from biological origins to individualized therapies, Clin Cancer Res Off J Am Assoc Cancer Res, vol.17, issue.1, pp.19-30, 2011. ,
Reduceddose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion, Arthritis Rheum, vol.63, issue.3, pp.603-611, 2011. ,
B cell biomarkers of rituximab responses in systemic lupus erythematosus: B Cell Biomarkers in Rituximab Therapy for SLE, Arthritis Rheum, vol.63, issue.10, pp.3038-3085, 2011. ,
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review, BioDrugs Clin Immunother Biopharm Gene Ther, 2017. ,
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a metaanalysis, Ann Rheum Dis, vol.72, issue.12, pp.1947-55, 2013. ,
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum, vol.54, issue.3, pp.711-716, 2006. ,
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis, vol.66, issue.7, pp.921-927, 2007. ,
,
, Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study, Ann Rheum Dis, vol.69, issue.5, pp.817-838, 2010.
Immunogenicity of biologic agents: a new concern for the practicing rheumatologist?, Curr Rheumatol Rep, vol.9, issue.4, pp.265-272, 2007. ,
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies. Mult Scler Houndmills Basingstoke Engl, 2017. ,
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab, Arthritis Rheum, vol.54, issue.12, pp.3782-3791, 2006. ,
Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies, J Eur Acad Dermatol Venereol JEADV, vol.28, issue.11, pp.1424-1454, 2014. ,
Dijkmans B a. C. Dealing with immunogenicity of biologicals: assessment and clinical relevance, Curr Opin Rheumatol, vol.21, issue.3, pp.211-216, 2009. ,
Immunogenicity to Biotherapeutics -The Role of Anti-drug Immune Complexes. Front Immunol, vol.7, 2016. ,
Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome, J Am Soc Nephrol JASN, vol.27, issue.6, pp.1811-1833, 2016. ,
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial, J Am Acad Dermatol, vol.16, issue.3, pp.534-576, 2004. ,
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis, J Am Acad Dermatol, vol.56, issue.1, pp.31-32, 2007. ,
Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura, Int J Hematol, vol.89, issue.3, pp.305-314, 2009. ,
Immunogenicity of biotherapy used in psoriasis: the science behind the scenes, J Invest Dermatol, vol.135, issue.1, pp.31-39, 2015. ,
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective, Ann Rheum Dis, vol.72, issue.2, pp.165-78, 2013. ,
Anti-TNF-? biotherapies: perspectives for evidence-based personalized medicine, Immunotherapy, vol.4, issue.11, pp.1167-79, 2012. ,
A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies, Ann Rheum Dis, vol.73, issue.6, pp.1138-1181, 2014. ,